Chemotherapy new approach reduces tumor size in Japanese patient Mesothelioma

Chemotherapy Mesothelioma

There is some potentially good news for mesothelioma patients who can not tolerate pemetrexed, the most popular drug for cancer chemotherapy asbestos.

A team of doctors in Japan are reporting a good response in a mesothelioma patient treated with a specially prepared paclitaxel in combination with carboplatin version.

Chemotherapy treatment for mesothelioma

Mesothelioma tumor of the patient is reduced once, but twice in this combination chemotherapy, suggesting that they may be a promising alternative to pemetrexed and cisplatin.

Malignant pleural mesothelioma is a very difficult disease to treat.

For mesothelioma patients who are not candidates for surgery, the most common treatment is a combination of pemetrexed (brand name Alimta) and a platinum-based drug called cisplatin.

Unfortunately, there are a number of toxicities associated with Alimta and even mesothelioma patients who can not tolerate the drug are limited in how much they can take. Mesothelioma patients who do not respond to pemetrexed have few alternatives.

A new type of chemotherapy Mesothelioma

Medical Center of Kyoto in Japan, doctors are reporting some encouraging results with a new type of chemotherapy for mesothelioma.

The approach uses a version of the chemotherapy drug paclitaxel that is enclosed in a sheath protein that makes it easier to enter cancer cells.

albumin-bound paclitaxel nanoparticles combined with carboplatin platinum drugs (nabPC) and given a 76-year-old patient with epithelioid mesothelioma mesothelioma who had not responded to standard chemotherapy.

Mesothelioma improve results

When the patient was given cisplatin and pemetrexed mesothelioma, mesothelioma the tumor continued to grow.

But when he received four cycles of nabPC, who had what his Japanese doctors describe as a “good response”. Equally important, when the man mesothelioma tumor began to grow again, again the doctors were able to slow its progression with four other cycles nabPC.

This is the first case of a patient of mesothelioma receive regression repeated this regimen and that could have an impact on the survival of mesothelioma tumor worldwide.

“Based on this case, nabPC is a potential alternative for malignant pleural mesothelioma, especially for MPM patients who can not tolerate chemotherapy drug pemetrexed,” writes study author Osamu Kanai with Kyoto Hospital National Medical Center Organization.

Approximately 2,500 Americans are diagnosed with malignant mesothelioma each year. The outlook for people with mesothelioma is generally poor.

Leave a comment